nystatin-a1 has been researched along with Bacteremia* in 3 studies
1 trial(s) available for nystatin-a1 and Bacteremia
| Article | Year |
|---|---|
Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation.
The goal of reducing oral complications during chemotherapy and bone marrow transplantation has received attention at several centers. The current randomized study of 86 adults with leukemia treated with chemotherapy or bone marrow transplantation assessed the potential role of chlorhexidine, nystatin, and saline solution rinses to reduce the findings of oral mucositis, gingivitis, and oral infection. The results of this study did not show a reduction in mucositis with the use of these rinses. However, potential bacterial and fungal pathogens were identified less frequently in the patients using chlorhexidine rinse. Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteremia; Bacteria; Bone Marrow Transplantation; Candidiasis, Oral; Chlorhexidine; Drug Combinations; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Mouth Diseases; Mouthwashes; Nystatin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stomatitis; Ulcer; Whole-Body Irradiation | 1992 |
2 other study(ies) available for nystatin-a1 and Bacteremia
| Article | Year |
|---|---|
In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections.
In this Letter, we presented in vitro studies of antimicrobial activity of Gly-His-Lys conjugates that are important point in preliminary biological evaluation of their potential application in skin and tissue therapies. The novel compounds include the conjugation of fatty acids with a modification of the amino acid sequence in the primary structure of Gly-His-Lys (6i). All the compounds exhibited strong to moderate activity. Compound 1d had the most potent antimicrobial activity at MIC ranges 31.3-125.0μg/mL (against Escherichia coli spp. and Staphylococcus aureus spp.), 375.0-500.0μg/mL (against Pseudomonas aeruginosa spp.). Conjugate 5b expressed activity against Staphylococcus aureus spp. and Escherichia coli spp. at MIC ranges 250.0-500.0μg/mL and 62.5-125.0μg/mL, respectively. Both conjugates 1d and 5b possessed rapid bactericidal activity against Gram-positive bacteria at 2MIC or 4MIC. Conjugates 1b-c, 1e, 2a-b and 4b showed noticeable effect against both Gram-positive and Gram-negative bacteria. Compounds 1d, 1e and 2e were the most active against fungus. Topics: Anti-Infective Agents; Bacteremia; Escherichia coli; Fungi; Humans; Microbial Sensitivity Tests; Oligopeptides; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus aureus | 2015 |
Systemic candidiasis (moniliasis) complicating treatment of bacterial endocarditis, with review of literature and report of apparent cure of one case with parenteral mycostatin.
Topics: Anti-Bacterial Agents; Bacteremia; Candidiasis; Endocarditis, Bacterial; Humans; Nystatin; Sepsis | 1958 |